WaveMan
WaveMan · Company
KOD · Kodiak Sciences Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

KOD Kodiak Sciences (KOD) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001468748
Quote by TradingView
Form 144 · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
118
13F, latest reported quarter
Conversions, 180 days
6
Codes C/M, not in net · $5.5M priced

What the filings say about KOD

Insiders, 180 days
+$153.3M net bought
1 buyer · 1 seller · 80% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$2.8M
1 notice

Kodiak Sciences insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Kodiak Sciences Inc. insiders bought a net $153.3M of stock across 239 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
BORGESON JOHN A.
Chief Financial Officer
SELL
2026-10-23 SECtraded 2026-10-21
8,514
$746.4K
n/a
Context
  • 15 earlier Form 4 trades (code P or S) here by this insider (15 sales), the last on Jun 4, 2026.
  • The trade is 3.6% of the 233,416 shares held after it.
  • No other insider sold within 30 days.
  • 118 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer BORGESON JOHN A. sold about $746.4K of KOD under a 10b5-1 plan on Oct 21, 2026; 118 funds added in the latest 13F quarter.
BORGESON JOHN A.
Chief Financial Officer
SELL
2026-10-23 SECtraded 2026-10-21
1,677
$149.6K
n/a
Context
  • 15 earlier Form 4 trades (code P or S) here by this insider (15 sales), the last on Jun 4, 2026.
  • The trade is 0.7% of the 231,739 shares held after it.
  • No other insider sold within 30 days.
  • 118 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer BORGESON JOHN A. sold about $149.6K of KOD under a 10b5-1 plan on Oct 21, 2026; 118 funds added in the latest 13F quarter.
BORGESON JOHN A.
Chief Financial Officer
SELL
2026-10-23 SECtraded 2026-10-21
7,623
$684.1K
n/a
Context
  • 15 earlier Form 4 trades (code P or S) here by this insider (15 sales), the last on Jun 4, 2026.
  • The trade is 3.4% of the 224,116 shares held after it.
  • No other insider sold within 30 days.
  • 118 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer BORGESON JOHN A. sold about $684.1K of KOD under a 10b5-1 plan on Oct 21, 2026; 118 funds added in the latest 13F quarter.
BORGESON JOHN A.
Chief Financial Officer
SELL
2026-10-23 SECtraded 2026-10-21
5,101
$464.1K
n/a
Context
  • 15 earlier Form 4 trades (code P or S) here by this insider (15 sales), the last on Jun 4, 2026.
  • The trade is 2.3% of the 219,015 shares held after it.
  • No other insider sold within 30 days.
  • 118 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer BORGESON JOHN A. sold about $464.1K of KOD under a 10b5-1 plan on Oct 21, 2026; 118 funds added in the latest 13F quarter.
BORGESON JOHN A.
Chief Financial Officer
SELL
2026-10-23 SECtraded 2026-10-21
2,985
$273.9K
n/a
Context
  • 15 earlier Form 4 trades (code P or S) here by this insider (15 sales), the last on Jun 4, 2026.
  • The trade is 1.4% of the 216,030 shares held after it.
  • No other insider sold within 30 days.
  • 118 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer BORGESON JOHN A. sold about $273.9K of KOD under a 10b5-1 plan on Oct 21, 2026; 118 funds added in the latest 13F quarter.
239 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 234 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$153.3M over 180 days
+$154.3M over 90 days · +$157.0M of it by a 10%+ holder
the highest in Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
118 funds bought in last quarter
more than 75% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
25.4% of the float short (float per yahoo 2026-10-26) · 1.8 days to cover · settled 2026-09-30
more than 85% of Pharma & Biotech
What changed in the last 30 days
Oct 23Chief Financial Officer BORGESON JOHN A. sold $2.7M under a 10b5-1 plan (Oct 21)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 21Officer JOHN BORGESON filed to sell $2.8M by Oct 21 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Sep 30Director BAKER BROS. ADVISORS LP bought $157.0M (82 trades, Sep 28 to Sep 29)

Watch KOD

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+385.5%12M
-6%+147%+300%+453%2025-102025-122026-022026-042026-062026-082026-10 2025-12-18 · Baker Brothers Life Sciences LP bought $55.0M2026-09-28 · BAKER BROS. ADVISORS LP bought $20.2M2026-09-28 · BAKER BROS. ADVISORS LP bought $17.7M2026-09-28 · BAKER BROS. ADVISORS LP bought $10.4M2026-09-28 · BAKER BROS. ADVISORS LP bought $9.6M2026-09-28 · BAKER BROS. ADVISORS LP bought $9.3M2026-09-28 · BAKER BROS. ADVISORS LP bought $8.7M2026-09-28 · BAKER BROS. ADVISORS LP bought $7.4M2026-09-28 · BAKER BROS. ADVISORS LP bought $6.6M2026-09-28 · BAKER BROS. ADVISORS LP bought $5.8M2026-09-28 · BAKER BROS. ADVISORS LP bought $5.7M2026-09-28 · BAKER BROS. ADVISORS LP bought $5.5M2025-12-18 · Baker Brothers Life Sciences LP bought $5.0M2026-09-28 · BAKER BROS. ADVISORS LP bought $4.7M2026-09-28 · BAKER BROS. ADVISORS LP bought $3.9M2026-09-28 · BAKER BROS. ADVISORS LP bought $3.7M2026-09-28 · BAKER BROS. ADVISORS LP bought $3.3M2026-09-28 · BAKER BROS. ADVISORS LP bought $2.8M2026-09-28 · BAKER BROS. ADVISORS LP bought $2.7M2026-09-28 · BAKER BROS. ADVISORS LP bought $2.4M2026-09-28 · BAKER BROS. ADVISORS LP bought $2.3M2026-09-29 · BAKER BROS. ADVISORS LP bought $1.7M2026-09-28 · BAKER BROS. ADVISORS LP bought $1.6M2026-09-28 · BAKER BROS. ADVISORS LP bought $1.4M2026-09-28 · BAKER BROS. ADVISORS LP bought $1.4M2026-09-28 · BAKER BROS. ADVISORS LP bought $1.4M2026-09-28 · BAKER BROS. ADVISORS LP bought $1.3M2026-09-28 · BAKER BROS. ADVISORS LP bought $1.2M2026-09-28 · BAKER BROS. ADVISORS LP bought $1.2M2026-09-28 · BAKER BROS. ADVISORS LP bought $1.1M2026-06-04 · BORGESON JOHN A. sold $880.7K2026-09-28 · BAKER BROS. ADVISORS LP bought $878.0K2026-09-29 · BAKER BROS. ADVISORS LP bought $874.5K2026-10-21 · BORGESON JOHN A. sold $746.4K2026-09-28 · BAKER BROS. ADVISORS LP bought $711.1K2026-10-21 · BORGESON JOHN A. sold $684.1K2026-09-28 · BAKER BROS. ADVISORS LP bought $620.4K2026-09-28 · BAKER BROS. ADVISORS LP bought $569.8K2026-09-28 · BAKER BROS. ADVISORS LP bought $556.1K2026-09-28 · BAKER BROS. ADVISORS LP bought $544.2K2026-09-28 · BAKER BROS. ADVISORS LP bought $520.8K2026-09-28 · BAKER BROS. ADVISORS LP bought $516.8K2026-10-21 · JOHN BORGESON filed to sell $2.8M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns KOD: institutional holders (13F)

13F holdings, latest reported quarter
BAKER BROS. ADVISORS LP
19,919,186 sh
$776.1M
BlackRock, Inc.
4,135,355 sh
$161.1M
STATE STREET CORP
2,419,417 sh
$94.3M
GOLDMAN SACHS GROUP INC
2,316,014 sh
$90.2M
VANGUARD CAPITAL MANAGEMENT LLC
1,804,632 sh
$70.3M

Congress trades in KOD

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

KOD planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
JOHN BORGESON
Filed 2026-10-21
$2.8M

KOD mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
BRUCE FUND
$5.6M position · as of 2026-06-30
1.5%
Invesco Dorsey Wright SmallCap Momentum ETF
$5.7M position · as of 2026-05-31
1.4%
Artisan International Small-Mid Fund
$23.2M position · as of 2026-06-30
0.9%
Virtus Biotech Clinical Trials Etf
$379.4K position · as of 2026-07-31
0.8%
State Street(R) SPDR(R) S&P(R) Biotech ETF
$58.3M position · as of 2026-06-30
0.5%
PROFUND VP BIOTECHNOLOGY
$258.3K position · as of 2026-06-30
0.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
12 registered trials, 4 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 1
0 active
10
Phase 3
4 active
1
Multi-phase
0 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$2.5M
$24.4M
$1.6M
+290%
n/a
2024
$2.0M
$11.3M
$1.4M
-88%
n/a
2023
$2.7M
-$830.5K
$1.5M
-96%
n/a
2022
$3.0M
-$118.8M
$1.6M
-92%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $153.3M bought by insiders over 180 days, 118 funds added last quarter, $2.8M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

KOD financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$159.9M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-368.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-94.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-114.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-2.9%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$234.4M-$186.8M-$277.3M-$341.4M
Net income-$230.0M-$176.2M-$260.5M-$333.8M
EPS (diluted)-4.32-3.35-4.97-6.39
Operating cash flow-$136.0M-$117.3M-$154.2M-$206.5M
Cash$209.9M$168.1M$285.5M$190.4M
SEC XBRL, fiscal years, as known on 2026-10-27

KOD Stock Sonar score 4/7 axes

Find similar shapesCompare

KOD ranks highest on insider conviction (78th percentile) and institutional and government (75th), and lowest on risk and compliance (8th), among Pharma & Biotech peers.

Profitability
20
Inputs
  • Return on equity-368.4% · 10 pct, sector of 545
  • Return on assets-94.2% · 26 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-114.7% · 22 pct, sector of 576
Insider conviction
78
Inputs
  • Net Form 4 buying (codes P and S), 180d$156.0M · 100 pct, sector of 428
  • Insider buyers, 180d1 · 56 pct, sector of 437
Institutional and government
75
Inputs
  • Funds adding, latest quarter118 · 75 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
8
Inputs
  • Short interest, % of float+25.4% · 8 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Financial health, Growth, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

KOD filings, in plain words

Are Kodiak Sciences insiders buying or selling KOD?

In the 180 days to 2026-10-27, Kodiak Sciences insiders were net buyers, a net $153.3M: $157.0M of purchases and $3.7M of sales reported on Form 4, by 1 buyer and 1 seller.

Are there planned insider sales of KOD?

Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-27, covering $2.8M of stock; the latest, by JOHN BORGESON, was filed 2026-10-21.

Read the full summary

In the 180 days to 2026-10-27, Kodiak Sciences insiders were net buyers of KOD, a net $153.3M across purchases and sales reported on Form 4 by 1 buyer and 1 seller. Most of that figure, $157.0M, came from a holder of 10% or more rather than an officer or director. Purchases outweighed sales more than tenfold by value. 80% of the 10 insider sales were made under a pre-arranged Rule 10b5-1 plan, so most selling was scheduled in advance. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-27, covering $2.8M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies